Author:
Wonderling David,Mariani Alfredo,Samarasekera Eleanor J,Wilkinson Colin,Patel Riyaz S,Mills Joseph
Reference21 articles.
1. Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK
2. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
3. Connelly D Cohen D McCartney M . Fewer than 5,000 people prescribed anticholesterol drug inclisiran in primary care as of July 2023. Pharm J 2023;2023. https://pharmaceutical-journal.com/article/news/fewer-than-5000-people-prescribed-anticholesterol-drug-inclisiran-in-primary-care-as-of-july-2023.
4. CVDPrevent audit. CVDP009CHOL: Percentage of patients aged 18 and over with GP recorded CVD (narrow definition), who are currently treated with lipid lowering therapy. https://www.cvdprevent.nhs.uk/data-explorer?period=10&area=1&indicator=34.
5. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice